NEOG · Neogen Corporation
$12.19
+1.75% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
27.1
Dividend yield
0.0%
Beta
1.79
Avg volume
3M
Employees
3K
Daily Change %
1.75%
5 Days Change
4.82%
10 Days Change
0.49%
30 Days Change
-10.76%
60 Days Change
4.73%
Month to Day Change
-0.41%
Year to Day Change
74.39%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NEOG
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-30
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Guggenheim | Maintains | Buy | $12.00 → $14.00 |
| 2026-08-26 | Piper Sandler | Upgrade | Neutral → Overweight | $13.00 → $14.00 |
| 2026-08-03 | Piper Sandler | Reiterates | Neutral | $11.00 → $13.00 |
| 2026-01-12 | Piper Sandler | Reiterates | Neutral | $6.50 → $10.00 |
| 2026-01-09 | Guggenheim | Maintains | Buy | $8.00 → $12.00 |
| 2025-12-10 | CJS Securities | Upgrade | Market Perform → Market Outperform | $0.00 → $10.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading -0.0% above the 50-day MA ($12.19).
- bullish: Price vs 200-day MA: Trading 17.8% above the 200-day MA ($10.35).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($5.41) and high ($13.98).
NEOG Price Chart
Loading chart for NEOG…
Fundamentals
About Neogen Corporation
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.